Renaissance Technologies’s Avalo Therapeutics AVTX Stock Holding History

Renaissance Technologies’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.6M	Buy	357,200 +237,086	+197%	+$3.75M	0.01%	1294
2026 Q1	$1.79M	Buy	120,114 +101,814	+556%	+$1.59M	﹤0.01%	1957
2025 Q4	$332K	Sell	18,300 -80,400	-81%	-$1.36M	﹤0.01%	2724
2025 Q3	$1.25M	Buy	+98,700	New	+$849K	﹤0.01%	2371
2022 Q3	–	Sell	-118	Closed	-$170K	–	4014
2022 Q2	$170K	Sell	118 -9	-7%	-$12K	﹤0.01%	3707
2022 Q1	$266K	Buy	127 +113	+807%	+$284K	﹤0.01%	3522
2021 Q4	$68K	Buy	14 +4	+40%	+$24K	﹤0.01%	3748
2021 Q3	$61K	Buy	+10	New	+$81.1K	﹤0.01%	3364
2021 Q2	–	Sell	-99	Closed	-$860K	–	3445
2021 Q1	$860K	Buy	99 +62	+168%	+$586K	﹤0.01%	2669
2020 Q4	$284K	Sell	37 -32	-46%	-$222K	﹤0.01%	3052
2020 Q3	$451K	Sell	69 -99	-59%	-$744K	﹤0.01%	2846
2020 Q2	$1.26M	Buy	+168	New	+$1.22M	﹤0.01%	2433
2019 Q3	–	Sell	-12	Closed	-$181K	–	3421
2019 Q2	$181K	Buy	+12	New	+$182K	﹤0.01%	3320

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies's AVTX Position: Q2 2026 in Review

Renaissance Technologies increased its Avalo Therapeutics (AVTX) stake by 197% in Q2 2026, buying an estimated $3.75M and bringing the position to 357,200 shares worth $6.6M. The position accounts for 0.01% of the portfolio, ranked #1294.

Renaissance Technologies first reported a position in AVTX in Q2 2019 and has held it in 13 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Renaissance Technologies held 357,200 shares of Avalo Therapeutics worth $6.6M as of Q2 2026.
Renaissance Technologies bought 237,086 Avalo Therapeutics shares in Q2 2026, an estimated $3.75M.
Avalo Therapeutics made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1294 holding.
Renaissance Technologies first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 13 quarters since.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.